S 2665
115th Congress
Senate
Health
Administrative law and regulatory procedures
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Food and Drug Administration (FDA)
Government information and archives
Health information and medical records
Medical ethics
Prescription drugs
A bill to require guidance on how the Food and Drug Administration will consider claims of opioid sparing and on the conditions under which the Food and Drug Administration will consider misuse and abuse of drugs in making certain determinations of safety.
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 12, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 12, 2018
Introduced in Senate
Plain-English summary
This bill requires the Food and Drug Administration (FDA) to develop guidance regarding how it will assess evidence to support claims of opioid sparing (i.e., the use of drugs that reduce pain while also allowing reduced use or avoidance of oral opioids) for non-opioid or other non-addictive medical products intended to treat pain.
The FDA must also develop guidance regarding how it will consider the misuse and abuse of drugs in making certain determinations of safety.
What's happening now
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
1